ChemFaces is a professional high-purity natural products manufacturer.
Product Intended Use
1. Reference standards
2. Pharmacological research
3. Inhibitors
Citing Use of our Products
How to Order
Orders via your E-mail:
1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Sent to Email: info@chemfaces.com
Contact Us
Order & Inquiry & Tech Support
Tel: (0086)-27-84237683
Fax: (0086)-27-84254680
E-mail: manager@chemfaces.com
Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
Delivery time
Delivery & Payment method
1. Usually delivery time: Next day delivery by 9:00 a.m. Order now
2. We accept: Wire transfer & Credit card & Paypal & Western Union
* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
| Size /Price /Stock |
10 mM * 1 mL in DMSO / $11.8 / In-stock |
Other Packaging |
*Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap |
More articles cited ChemFaces products.
Molecules.2020, 25(9):2081.Chem Pharm Bull (Tokyo)....2017...Sci Rep.2020, 10:4495(2020)Asian J Beauty Cosmetol...2020...LWT2021, 150:112021.European Journal of Integrative M...2018...J of l. Chroma.&Related Tech...2020...Plant Methods.2017, 13:108
Acta Pharm Sin B.2015, 5(4):323-9.Sci Rep.2016, 6:25094J Agric Food Chem....2020...J Ethnopharmacol.2022, 282:114574. Front Plant Sci.2018, 9:1424Green Chemistry2021, ISSUE 2.J Ethnopharmacol.2017, 198:205-213Natural Product Communications...2020...
Biosci Biotechnol Biochem....2020...J Pharmaceutical Research Int....2021...United States Patent Application...2020...Korean Journal of Pharmacognosy...2017...Oncotarget.2017, 8(53):90925-90947Front Microbiol.2021, 12:736780.J Biochem Mol Toxicol....2020...
More...
Our products had been exported to the following research institutions and universities, And still growing.
University Medical Center Mainz (Germany)University of Illinois (USA)Auburn University (USA)Universidad de Buenos Aires (Argentina)
Lodz University of Technology (Poland)Sanford Burnham Medical Researc... (USA)Leibniz Institute of Plant Bioc... (Germany)Universidad de Ciencias y Artes... (Mexico)
Gyeongsang National University (Korea)Srinakharinwirot University (Thailand)Molecular Biology Institute of ... (Spain)
More...
Atropine
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Appl. Sci. 2021, 11(22), 10552Sci Rep.2019, 9(1):6429Front Aging Neurosci.2019, 11:230Toxicol In Vitro.2018, 52:94-105Biomolecules.2019, 9(11):E696United States Patent Application2020, 20200038363Korean Journal of Medicinal Crop Science2018, 26(5):382-390Chemistry of Plant Materials.2019, 129-136Natural Product Communications2020, doi: 10.1177.J Liq Chromatogr R T2018, 41(12):761-769
Related Screening Libraries
| Description: |
Atropine is a competitive antagonist of the muscarinic acetylcholine receptors (acetylcholine being the main neurotransmitter used by the parasympathetic nervous system), used to treat certain types of nerve agent and pesticide poisonings, some types of slow heart rate, and to decrease saliva production during surgery. |
| Targets: |
AChR |
| In vitro: |
| J Pediatr Ophthalmol Strabismus. 2014 Nov-Dec;51(6):363-9. | | Use of atropine penalization to treat amblyopia in UK orthoptic practice.[Pubmed: 25427306] | To compare clinical practice patterns regarding Atropine penalization use by UK orthoptists to the current evidence base and identify any existing barriers against use of AP as first-line treatment.
METHODS AND RESULTS:
An online survey was designed to assess current practice patterns of UK orthoptists using Atropine penalization. They were asked to identify issues limiting their use of Atropine penalization and give opinions on its effectiveness compared to occlusion. Descriptive statistics and content analysis were applied to the results. Responses were obtained from 151 orthoptists throughout the United Kingdom. The main perceived barriers to use of Atropine penalization were inability to prescribe Atropine and supply difficulties. However, respondents also did not consider Atropine penalization as effective as occlusion in treating amblyopia, contrary to recent research findings. Patient selection criteria and treatment administration largely follow current evidence. More orthoptists use Atropine penalization as first-line treatment than previously reported.
CONCLUSIONS: Practitioners tend to closely follow the current evidence base when using Atropine penalization, but reluctance in offering it as first-line treatment or providing a choice for parents between occlusion and Atropine still remains.
This may result from concerns regarding Atropine's general efficacy, side effects, and risk of reverse amblyopia. Alternatively, as demonstrated in other areas of medicine, it may reflect the inherent delay of research findings translating to clinical practice changes. |
|
| In vivo: |
| J Community Support Oncol. 2015 Jan;13(1):3-7. | | Use of atropine-diphenoxylate compared with hyoscyamine to decrease rates of irinotecan-related cholinergic syndrome.[Pubmed: 25839059] | To compare the incidence of cholinergic syndrome with irinotecan using Atropine-diphenoxylate or hyoscyamine as premedication.
METHODS AND RESULTS:
We conducted a retrospective, single-center, nonrandomized, cohort study of adult patients treated with Atropine-diphenoxylate or hyoscyamine as premedication before receiving irinotecan. For all irinotecan infusions, intravenous Atropine was administered for patients experiencing any cholinergic reaction. A total of 532 irinotecan cycles (354 cycles for Atropine-diphenoxylate group; 178 cycles for hyoscyamine group) were analyzed in 80 patients. Overall incidence of cholinergic syndrome did not differ between Atropine-diphenoxylate (8.2%) and hyoscyamine (9.0%) groups (P = .76). The incidence of cholinergic syndrome after the £rst cycle of irinotecan was similar between the 2 arms, Atropine-diphenoxylate (14.6%) and hyoscyamine (10.7%), with P = .74. The most common cholinergic symptoms documented were abdominal pain or cramping, and diarrhea. This study was subjected to vulnerabilities to bias and random error because of its observational retrospective design and small number of participants.
CONCLUSIONS:
Lack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests Atropinediphenoxylate and hyoscyamine may both be effective prophylactic options. The findings support the need for a larger, randomized study to assess and compare these agents with other potential premedications such as scopolamine and Atropine in prevention of irinotecan-related cholinergic syndrome. | | Ther Adv Cardiovasc Dis. 2014 Oct;8(5):176-84. | | Atropine first is safer than conventional atropine administration in older people undergoing dobutamine stress echocardiography.[Pubmed: 24906705] | Early injection of Atropine during dobutamine stress echocardiography (DSE) has been demonstrated in retrospective analyses to reduce the duration and dose of dobutamine infusion, while preserving a similar diagnostic accuracy with a lower incidence of adverse effects. This study explores the safety of using Atropine as a start drug before dobutamine infusion (ADSE protocol) in comparison with the conventional protocol (DASE protocol) in older patients undergoing DSE for ischemia evaluation.
METHODS AND RESULTS:
One hundred consecutive older patients were prospectively enrolled. When eligible, they were randomly assigned to undergo either the DASE protocol (group A, 50 patients) or the ADSE protocol (group B, 50 patients) when Atropine (1.0 mg) was first administered 3 min before dobutamine infusion followed by 0.5 mg increments (maximum 1.0 mg) thereafter. Patients were monitored for adverse drug effects. Test duration was calculated.
The mean age of the whole study cohort was 67.8±4.3 years and 58 (58%) were men. Patients in group A had longer test duration (21.8±1.3 versus 13.7±0.77 min, p<0.001) and higher mean dobutamine infusion rate (39±8.2 versus 28.2±9.5 μg/kg/min, p<0.001). The two groups received a similar total dose of Atropine. Group A patients showed significantly higher incidence of extrasystoles, nonsustained ventricular tachycardia and severe hypotension (p<0.05).
CONCLUSIONS:
In older patients undergoing DSE, using Atropine as a start drug, that is, adopting the ADSE protocol, is associated with shorter test duration, lower mean dobutamine infusion rate and consequently fewer adverse effects. |
|
Atropine Description
| Source: |
The herbs of Atropa belladonna L. |
| Solvent: |
Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc. |
| Storage: |
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
|
| After receiving: |
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling. |
ChemFaces New Products and Compounds
Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.
IF=36.216(2019)PMID: 29328914
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.
IF=22.415(2019)PMID: 32004475
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.
IF=14.548(2019)PMID: 29149595
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.
IF=13.903(2019)PMID: 29553709
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.
IF=13.297(2019)PMID: 28005066
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.
IF=12.804(2019)PMID: 30417089
Calculate Dilution Ratios(Only for Reference)
|
1 mg |
5 mg |
10 mg |
20 mg |
25 mg |
| 1 mM |
3.4554 mL |
17.2771 mL |
34.5543 mL |
69.1085 mL |
86.3856 mL |
| 5 mM |
0.6911 mL |
3.4554 mL |
6.9109 mL |
13.8217 mL |
17.2771 mL |
| 10 mM |
0.3455 mL |
1.7277 mL |
3.4554 mL |
6.9109 mL |
8.6386 mL |
| 50 mM |
0.0691 mL |
0.3455 mL |
0.6911 mL |
1.3822 mL |
1.7277 mL |
| 100 mM |
0.0346 mL |
0.1728 mL |
0.3455 mL |
0.6911 mL |
0.8639 mL |
* Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
